209 related articles for article (PubMed ID: 12947386)
1. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation.
Powell SN; Kachnic LA
Oncogene; 2003 Sep; 22(37):5784-91. PubMed ID: 12947386
[TBL] [Abstract][Full Text] [Related]
2. Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology.
Stecklein SR; Jensen RA
Transl Res; 2012 Sep; 160(3):178-97. PubMed ID: 22683426
[TBL] [Abstract][Full Text] [Related]
3. TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms.
Nichols KE; Heath JA; Friedman D; Biegel JA; Ganguly A; Mauch P; Diller L
J Clin Oncol; 2003 Dec; 21(24):4505-9. PubMed ID: 14673037
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 regulates RAD51 function in response to DNA damage and suppresses spontaneous sister chromatid replication slippage: implications for sister chromatid cohesion, genome stability, and carcinogenesis.
Cousineau I; Abaji C; Belmaaza A
Cancer Res; 2005 Dec; 65(24):11384-91. PubMed ID: 16357146
[TBL] [Abstract][Full Text] [Related]
5. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
6. The potential of PARP inhibitors in genetic breast and ovarian cancers.
Drew Y; Calvert H
Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
[TBL] [Abstract][Full Text] [Related]
7. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
[TBL] [Abstract][Full Text] [Related]
8. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization.
Jönsson G; Naylor TL; Vallon-Christersson J; Staaf J; Huang J; Ward MR; Greshock JD; Luts L; Olsson H; Rahman N; Stratton M; Ringnér M; Borg A; Weber BL
Cancer Res; 2005 Sep; 65(17):7612-21. PubMed ID: 16140926
[TBL] [Abstract][Full Text] [Related]
9. [A paradox and three egnimas about the role of BRCA1 in breast and ovarian cancers].
Feunteun J
J Soc Biol; 2004; 198(2):123-6. PubMed ID: 15368961
[TBL] [Abstract][Full Text] [Related]
10. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
11. Hereditary ovarian cancer.
Prat J; Ribé A; Gallardo A
Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
[TBL] [Abstract][Full Text] [Related]
12. Genetic variations in DNA repair genes, radiosensitivity to cancer and susceptibility to acute tissue reactions in radiotherapy-treated cancer patients.
Chistiakov DA; Voronova NV; Chistiakov PA
Acta Oncol; 2008; 47(5):809-24. PubMed ID: 18568480
[TBL] [Abstract][Full Text] [Related]
13. BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II.
Treszezamsky AD; Kachnic LA; Feng Z; Zhang J; Tokadjian C; Powell SN
Cancer Res; 2007 Aug; 67(15):7078-81. PubMed ID: 17671173
[TBL] [Abstract][Full Text] [Related]
14. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation.
DelloRusso C; Welcsh PL; Wang W; Garcia RL; King MC; Swisher EM
Mol Cancer Res; 2007 Jan; 5(1):35-45. PubMed ID: 17259345
[TBL] [Abstract][Full Text] [Related]
15. Counseling for male BRCA mutation carriers: a review.
Mohamad HB; Apffelstaedt JP
Breast; 2008 Oct; 17(5):441-50. PubMed ID: 18657973
[TBL] [Abstract][Full Text] [Related]
16. Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients.
Choi DH; Lee MH; Bale AE; Carter D; Haffty BG
J Clin Oncol; 2004 May; 22(9):1638-45. PubMed ID: 15117986
[TBL] [Abstract][Full Text] [Related]
17. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
[TBL] [Abstract][Full Text] [Related]
18. Deletions of BRCA1/2 and p53 R248W gain-of-function mutation suggest impaired homologous recombination repair in fragile histidine triad-negative sebaceous gland carcinomas.
Becker K; Goldberg M; Helmbold P; Holbach LM; Loeffler KU; Ballhausen WG
Br J Dermatol; 2008 Dec; 159(6):1282-9. PubMed ID: 18717684
[TBL] [Abstract][Full Text] [Related]
19. Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.
King TA; Li W; Brogi E; Yee CJ; Gemignani ML; Olvera N; Levine DA; Norton L; Robson ME; Offit K; Borgen PI; Boyd J
Ann Surg Oncol; 2007 Sep; 14(9):2510-8. PubMed ID: 17597348
[TBL] [Abstract][Full Text] [Related]
20. Germline mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma.
Kim YT; Nam EJ; Yoon BS; Kim SW; Kim SH; Kim JH; Kim HK; Koo JS; Kim JW
Gynecol Oncol; 2005 Dec; 99(3):585-90. PubMed ID: 16084575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
